284030-57-5

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-2,3-DIFLUORO-5-NITRO-BENZOIC ACID is used as a key intermediate in the synthesis of various drugs and pharmaceuticals, contributing to the development of new medications.
Used in Antibacterial and Antifungal Applications:
4-AMINO-2,3-DIFLUORO-5-NITRO-BENZOIC ACID is used as an active ingredient in medications for its antibacterial and antifungal properties, helping to combat infections.
Used in Dye and Pigment Manufacturing:
4-AMINO-2,3-DIFLUORO-5-NITRO-BENZOIC ACID is used as a component in the manufacturing of dyes and pigments, leveraging its chemical properties for color production.
Safety Considerations:
Due to its chemical properties, 4-AMINO-2,3-DIFLUORO-5-NITRO-BENZOIC ACID should be handled with caution, and proper safety protocols must be followed during its use in various applications.

InChI:InChI=1/C7H4F2N2O4/c8-4-2(7(12)13)1-3(11(14)15)6(10)5(4)9/h1H,10H2,(H,12,13)

Upstream product

• 197520-71-1 2,3,4-trifluoro-5-nitro-benzoic acid 
• 61079-72-9 2,3,4,-trifluorobenzoic acid 

Downstream Products

• 284030-58-6 4-Amino-2,3-difluoro-5-nitro-benzoic acid methyl ester 
• 606143-94-6 4-amino-3-fluoro-2-(2-fluoro-phenylamino)-5-nitro-benzoic acid methyl ester 

Relevant academic research and scientific papers

FORMS OF BINIMETINIB AND PROCESS FOR PREPARATION THEREOF

Amorphous forms of Binimetinib and processes for the preparation thereof.

Substituted benzimidazole compound and composition with compound

The invention provides a substituted benzimidazole compound and a composition with the compound. The substituted benzimidazole compound is a compound of formula (I) as shown in the specification, or apharmaceutically acceptable salt, prodrug, aquo-complex or solvent compound, polycrystalline type compound, stereisomer or isotope variant of the compound. The compound provided by the invention canbe adopted to treat and/or prevent related diseases caused by MEK (Methyl Ethyl Ketone), such as excessive proliferative diseases, pancreatitis, kidney illness, blastocyte cell transplantation and angiogenesis or angiopoiesis related diseases.

COMBINATION THERAPY

The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)- amide or a pharmaceutically acceptable salt thereof and the IGFIR inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.

NOVEL HYDROGEN SULFATE SALT

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. Compound I

SNAr PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-2 and their synthetic intermediates: wherein X1, X2, X5, R1, R2 and R4 are as defined herein. Compounds of Formula Ia-2 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

PROCESS FOR PREPARING BENZIMIDAZOLE COMPOUNDS

Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ia-1 and their synthetic intermediates: wherein Z, X1, X2, X5, R2 and R10 are as defined herein. Compounds of Formula Ia-1 and their synthetic intermediates can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.

N3 alkylated benzimidazole derivatives as MEK inhibitors

Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, t, R1, R2, R7, R9, R10, R11 and R12 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.